| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
12,831 |
10,875 |
$2.33M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
17,416 |
15,280 |
$1.87M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,058 |
1,778 |
$804K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
8,342 |
1,983 |
$449K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
7,221 |
5,841 |
$364K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
26,317 |
20,236 |
$356K |
| 80053 |
Comprehensive metabolic panel |
21,203 |
16,497 |
$332K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,550 |
4,224 |
$321K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,613 |
2,333 |
$276K |
| G0378 |
Hospital observation service, per hour |
2,620 |
1,055 |
$222K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
4,619 |
3,930 |
$195K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,161 |
1,431 |
$185K |
| 36415 |
Collection of venous blood by venipuncture |
20,684 |
15,827 |
$184K |
| 59025 |
Fetal non-stress test |
2,789 |
1,002 |
$176K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
1,928 |
1,701 |
$167K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
554 |
475 |
$162K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
5,060 |
2,867 |
$150K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,707 |
2,868 |
$133K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,928 |
3,567 |
$131K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,644 |
2,862 |
$125K |
| 71046 |
Radiologic examination, chest; 2 views |
3,130 |
2,834 |
$123K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
1,000 |
844 |
$111K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,529 |
2,287 |
$108K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
5,864 |
4,935 |
$107K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,208 |
1,960 |
$93K |
| 71045 |
Radiologic examination, chest; single view |
4,404 |
3,797 |
$93K |
| 84484 |
|
6,288 |
4,369 |
$93K |
| 83735 |
|
3,391 |
2,408 |
$92K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,940 |
1,773 |
$88K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,935 |
1,769 |
$88K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,172 |
995 |
$86K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,337 |
742 |
$81K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,441 |
1,065 |
$80K |
| 81001 |
|
7,182 |
6,090 |
$78K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
9,917 |
7,691 |
$77K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,617 |
1,488 |
$73K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,776 |
2,945 |
$69K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,488 |
1,301 |
$66K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,899 |
1,699 |
$66K |
| 81025 |
|
2,155 |
1,786 |
$65K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
964 |
428 |
$65K |
| 83690 |
|
3,188 |
2,744 |
$59K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
970 |
911 |
$58K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,015 |
885 |
$54K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,406 |
3,626 |
$51K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
2,642 |
2,092 |
$51K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
158 |
152 |
$50K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
93 |
88 |
$48K |
| 82150 |
|
2,622 |
2,287 |
$47K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,968 |
2,547 |
$47K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
240 |
223 |
$47K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
667 |
550 |
$46K |
| 82550 |
|
4,697 |
3,977 |
$45K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,408 |
1,331 |
$42K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
2,412 |
2,051 |
$40K |
| 87070 |
|
1,636 |
1,449 |
$39K |
| J2704 |
Injection, propofol, 10 mg |
2,423 |
1,995 |
$39K |
| 81003 |
|
3,617 |
3,170 |
$39K |
| 97164 |
|
629 |
565 |
$37K |
| 83880 |
|
1,503 |
1,258 |
$37K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,542 |
2,278 |
$36K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,002 |
747 |
$34K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
101 |
79 |
$33K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
881 |
806 |
$33K |
| 85610 |
|
2,960 |
2,343 |
$33K |
| 93017 |
|
207 |
198 |
$33K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,341 |
377 |
$32K |
| 80305 |
|
1,584 |
1,350 |
$31K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
159 |
153 |
$31K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,195 |
944 |
$31K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
4,743 |
4,216 |
$31K |
| 80061 |
Lipid panel |
2,055 |
1,949 |
$30K |
| 93225 |
|
543 |
264 |
$29K |
| 97014 |
|
1,300 |
329 |
$29K |
| 71250 |
|
345 |
328 |
$27K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
707 |
537 |
$27K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
26 |
15 |
$27K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
275 |
263 |
$27K |
| 85730 |
|
1,586 |
1,413 |
$26K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
872 |
775 |
$26K |
| 93976 |
|
214 |
205 |
$25K |
| 87040 |
|
1,235 |
643 |
$24K |
| 82553 |
|
1,209 |
1,041 |
$24K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
230 |
144 |
$23K |
| J2785 |
Injection, regadenoson, 0.1 mg |
113 |
109 |
$23K |
| 87077 |
|
1,127 |
1,025 |
$22K |
| 82948 |
|
2,311 |
966 |
$22K |
| 87186 |
|
1,035 |
937 |
$22K |
| 83605 |
|
1,284 |
980 |
$21K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
184 |
167 |
$21K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
983 |
805 |
$20K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,071 |
997 |
$20K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,970 |
1,893 |
$19K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
118 |
113 |
$18K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
577 |
542 |
$18K |
| 73562 |
|
433 |
358 |
$16K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
499 |
447 |
$15K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
290 |
254 |
$15K |
| 73610 |
|
226 |
197 |
$15K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
288 |
273 |
$13K |
| 84702 |
|
388 |
282 |
$11K |
| 85379 |
|
528 |
468 |
$11K |
| 82607 |
|
712 |
660 |
$11K |
| 73030 |
|
304 |
266 |
$11K |
| 86850 |
|
666 |
611 |
$10K |
| 85027 |
|
855 |
729 |
$10K |
| 86803 |
|
497 |
479 |
$10K |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
368 |
231 |
$10K |
| 87634 |
|
168 |
158 |
$10K |
| 73130 |
|
117 |
103 |
$10K |
| 74018 |
|
238 |
203 |
$10K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
384 |
324 |
$10K |
| 86900 |
|
822 |
748 |
$9K |
| 96376 |
|
228 |
144 |
$9K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
1,748 |
1,023 |
$9K |
| 84439 |
|
319 |
279 |
$9K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
339 |
233 |
$8K |
| 97161 |
|
158 |
147 |
$7K |
| 73630 |
|
178 |
157 |
$7K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,861 |
2,100 |
$6K |
| 83655 |
|
389 |
376 |
$6K |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
192 |
174 |
$6K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
193 |
175 |
$6K |
| 96523 |
|
186 |
141 |
$6K |
| 74019 |
|
130 |
112 |
$5K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
95 |
89 |
$5K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
15 |
13 |
$5K |
| 87481 |
|
59 |
24 |
$5K |
| 87581 |
|
65 |
61 |
$5K |
| 87205 |
|
328 |
266 |
$5K |
| 87486 |
|
64 |
61 |
$5K |
| 87420 |
|
150 |
119 |
$5K |
| 74022 |
|
39 |
39 |
$5K |
| 82728 |
|
344 |
322 |
$5K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
59 |
44 |
$5K |
| 72100 |
|
92 |
88 |
$5K |
| 76830 |
Ultrasound, transvaginal |
85 |
80 |
$4K |
| 86592 |
|
438 |
412 |
$4K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
105 |
82 |
$4K |
| 82746 |
|
292 |
260 |
$4K |
| 86901 |
|
671 |
611 |
$4K |
| 87340 |
|
248 |
233 |
$4K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
32 |
26 |
$4K |
| A4212 |
Non-coring needle or stylet with or without catheter |
295 |
216 |
$4K |
| 97162 |
|
81 |
75 |
$4K |
| 86762 |
|
178 |
170 |
$4K |
| 93970 |
|
25 |
24 |
$3K |
| 73502 |
|
99 |
93 |
$3K |
| 83540 |
|
359 |
332 |
$3K |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
249 |
170 |
$3K |
| 12001 |
|
26 |
26 |
$3K |
| 82803 |
|
118 |
97 |
$3K |
| 82565 |
|
144 |
123 |
$3K |
| A4221 |
Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) |
530 |
263 |
$2K |
| 86140 |
|
304 |
260 |
$2K |
| 85651 |
|
66 |
56 |
$2K |
| 87075 |
|
92 |
83 |
$2K |
| 88304 |
|
48 |
37 |
$2K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
41 |
41 |
$2K |
| 11721 |
|
213 |
210 |
$2K |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
46 |
42 |
$2K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
15 |
15 |
$2K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
108 |
62 |
$1K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
90 |
26 |
$1K |
| 84520 |
|
106 |
89 |
$961.24 |
| 84703 |
|
57 |
42 |
$813.34 |
| 36591 |
|
96 |
52 |
$773.56 |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
36 |
27 |
$717.28 |
| 94799 |
|
34 |
24 |
$710.48 |
| 84145 |
|
171 |
149 |
$668.12 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
17 |
13 |
$590.27 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
16 |
13 |
$590.27 |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
15 |
14 |
$581.77 |
| 82950 |
|
97 |
91 |
$528.02 |
| 73110 |
|
30 |
29 |
$481.50 |
| G0008 |
Administration of influenza virus vaccine |
141 |
139 |
$449.41 |
| 73560 |
|
12 |
12 |
$437.23 |
| J1815 |
Injection, insulin, per 5 units |
47 |
27 |
$435.84 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
24 |
22 |
$419.89 |
| A6530 |
Gradient compression stocking, below knee, 18-30 mmhg, each |
97 |
91 |
$412.82 |
| 80074 |
|
13 |
12 |
$390.85 |
| 82043 |
|
85 |
76 |
$379.66 |
| 90715 |
|
26 |
24 |
$306.47 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
44 |
28 |
$300.99 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
26 |
12 |
$258.56 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
118 |
112 |
$253.77 |
| 94010 |
|
318 |
307 |
$238.96 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
247 |
231 |
$217.73 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
2,828 |
2,502 |
$191.81 |
| 84153 |
|
12 |
12 |
$155.98 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
16 |
14 |
$154.32 |
| 73620 |
|
13 |
13 |
$103.39 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
12 |
12 |
$85.12 |
| 36600 |
|
13 |
12 |
$84.33 |
| 85045 |
|
25 |
24 |
$73.05 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
32 |
28 |
$53.90 |
| J7614 |
Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg |
26 |
12 |
$25.92 |
| A4223 |
Infusion supplies not used with external infusion pump, per cassette or bag (list drugs separately) |
21 |
17 |
$24.21 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
18 |
16 |
$10.60 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
12 |
12 |
$6.72 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
25 |
24 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
41 |
40 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
14 |
12 |
$0.00 |
| 90662 |
|
32 |
32 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
16 |
13 |
$0.00 |
| 90653 |
|
25 |
25 |
$0.00 |